

**NEW J Code** Effective January 1, 2007

# **DACOGEN™ (decitabine) for Injection**

## **J code J0894**



Effective January 1, 2007, CMS has assigned J0894 as the specific Healthcare Common Procedure Coding System (HCPCS) J code for DACOGEN to be used with third party payers in the physician office and hospital settings. The billing unit for this code is 1 mg. DACOGEN is supplied in a 50 mg single-dose vial.

DACOGEN is indicated for treatment of patients with myelodysplastic syndromes (MDS), including previously treated and untreated, *de novo* and secondary MDS of all French-American-British (FAB) subtypes (RA, RARS, RAEB, RAEB-t, CMML) and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System (IPSS) groups.

DACOGEN may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with DACOGEN. Men should be advised not to father a child while receiving treatment with DACOGEN, and for 2 months afterwards. The most commonly occurring adverse reactions include neutropenia, thrombocytopenia, anemia, pyrexia, fatigue, nausea, cough, petechiae, constipation, diarrhea, and hyperglycemia.

Please see the accompanying full prescribing information.



Dacogen is a trademark of SuperGen, Inc., Dublin, CA, U.S.A. used under license.  
Distributed and marketed by MGI PHARMA, INC., Bloomington, MN 55437  
© 2006 MGI PHARMA, INC., Bloomington, MN 55437 U.S.A. DAC0104 12/06

**DACOGEN™**  
decitabine for injection